Aldeyra (ALDX) announced that the European Medicines Agency has granted orphan designation for ADX-2191 for the treatment of primary large B-Cell lymphomas of immune-privileged sites, including primary vitreoretinal lymphoma. There is currently no approved treatment for patients with primary vitreoretinal lymphoma, a rare, aggressive, high-grade cancer that affects approximately 100 to 200 people per year in the European Union.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALDX:
- Aldeyra Therapeutics Gains FDA Fast Track for ADX-2191
- Aldeyra granted fast track designation for ADX-2191 by FDA
- Aldeyra Therapeutics: Positive NDA Resubmission and Strategic Advancements Support Buy Rating
- Buy Rating for Aldeyra Therapeutics Driven by FDA Progress and Strategic Partnership Potential
- Aldeyra receives orphan designation for ADX-2191 from EMA